As Lurbinectedin is being tested as a second line treatment for patients with relapsed small cell lung cancer after platinum based chemotherapy, can the use of drug releasing nanoparticles be a more focused delivery option for this drug?

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30068-1/fulltext

https://immuno-oncologynews.com/2020/02/24/fda-grants-priority-review-to-lurbinectedin-for-small-cell-lung-cancer/

More Marcela Nava's questions See All
Similar questions and discussions